TITLE:
Study Evaluating MAC-321 in Colorectal Cancer

CONDITION:
Colorectal Neoplasms

INTERVENTION:
MAC-321

SUMMARY:

      Assess the clinical activity of MAC-321 administered IV as a second-line or third-line
      antineoplastic agent to subjects with advanced colorectal cancer. Clinical activity will be
      assessed by determining the percentage of subjects exhibiting an objective response
      (complete plus partial responses). Tumor response will be assessed following modified
      Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histologic and/or cytologic diagnosis of metastatic or relapsed colorectal cancer at
             any time during disease but not candidates for surgical resection.

          -  Prior treatment with at least 1 conventional approved therapeutic regimen.

          -  Subjects who have failed prior cytotoxic chemotherapy regimens containing irinotecan
             (CPT-11), 5 fluorouracil (5-FU), and/or oxaliplatin for advanced (relapsed)
             metastatic colon cancer are eligible

        Exclusion Criteria:

          -  Other chemotherapy, radiotherapy, immunotherapy, or investigational agents within 4
             weeks before signing the ICF (6 weeks if the previous chemotherapy included
             nitrosoureas or mitomycin)

          -  Prior radiotherapy to >25% of bone marrow

          -  Prior exposure to MAC-321
      
